Company profile
Digitising clinical trials | Aparito
Aparito digitises clinical trials and unlocks real-world data through mobile apps, video assessments & wearable devices.
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
CS01 | Transaction MzQ0NDI1ODE0NWFkaXF6a2N4
Published 20 Nov 2024 10:14
Company registered at Companies House
1 Mar 2024 to 28 Feb 2027
Musculoskeletal (MSK) conditions affect many people, including problems in joints, bones and muscles and sometimes associated tissues such as nerves. Over 20 million people in the UK, almost 30% of the population, have an MSK condition such as arthritis or back pain. Symptoms can include pain, stiffness, limited movement, and disability, which affect inde...
1 Jan 2021 to 31 Dec 2021
1 Jul 2019 to 31 Mar 2020
The purpose of this project is to assess the utility of Atom 5, a direct patient-facing technology provided by Aparito, to improve adherence and persistence with oral anticoagulation through increased engagement with a cohort of elderly patients with atrial fibrillation (AF), the commonest form of heart rhythm disturbance that is responsible for over 20% ...
1 Dec 2017 to 31 Dec 2020
Epilepsy is one of the most common neurological disorders worldwide with over 500,000 suffers in South Africa (SA) alone. The prevalence of epilepsy in low to middle income countries is substantially greater than in more resourced countries - 81.7 compared with 45.0 per 100,000 and affects a younger population. Precision medicine aims to optimise therapeu...
